Clinical trials: Protein Deficiency
HIV Infections
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant…
- Trial name
- NCT04927585
- Testing
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
Anemia, Vitamin D Deficiency
Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period
The purpose of this study is to observe changes in iron status and vitamin D status during a 12-24 week supervised training program, specifically males and females between the ages of 30 and 50 years old.
- Trial name
- NCT01328704
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Avera McKennan Hospital & University Health Center
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
To determine the safety, immunogenicity, and optimal dose of rgp120/HIV-1MN octameric V3 peptide vaccine (SynVac) in healthy volunteers.
- Trial name
- NCT00000775
- Testing
- rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis
Transcriptome and Metabolic Analyses of CHAPLE Disease
CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, protein losing enteropathy) is a newly discovered genetic disorder, which is caused by deleterious mutations in the CD55 gene.
- Conditions
- CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis, Protein-Losing Enteropathies, Complement Regulatory Factor Defect
- Trial name
- CHAPLEOMIC (NCT03950804)
- Testing
- Eculizumab Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University
Diet, Healthy, Protein Deficiency
Protein and Performance (PROPER) in Endurance Athletes
The present study is a parallel group design with randomised allocation to either a 1) reduced protein diet (RP) or a 2) normal protein diet (NP).
- Trial name
- PROPER (NCT05426447)
- Testing
- Dietary intervention of reduced protein intake, Dietary intervention of normal protein intake
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Vitamin D Deficiency
Vitamin D in Armenia: Vitamin D Repletion Strategies With Dibase, and Vitamin D and Vitamin D Binding Protein and COVID
This is a three-arm unblinded prospective interventional study of vitamin D supplementation in participants with insufficient vitamin D at three different induction and maintenance dosing regimens (high dose, low frequency…
- Trial name
- NCT06406543
- Testing
- Vitamin D3 (Cholecalciferol)
- Where
- Armenia
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Columbia University
Vitamin D Deficiency
Isolation of Vitamin D Binding Protein Isoforms From Human Volunteers
The purpose of this study is to isolate genotype-specific DBP/Gc from homozygous human volunteers and use these purified proteins to cross-validate existing or novel assays for this serum protein and to evaluate the binding…
- Trial name
- NCT02258035
- Testing
- Blood draw
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Weight Loss, Muscle Loss
Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency
Military personnel face many physiological challenges, including sustained physical activity and prolonged periods of negative energy balance.
- Conditions
- Weight Loss, Muscle Loss, Bone Loss
- Trial name
- NCT01292395
- Testing
- Dietary Protein Intake
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- United States Army Research Institute of Environmental Medicine
Protein Deficiency, Training Group, Sensitivity
Effects of a Recovery Supplement on Body Composition, Performance, Muscular Properties, and Wellbeing
The investigation will be conducted as a double blinded, randomized, parallel between treatment conditions comparison design with two different groups ingesting a different supplement each one.
- Conditions
- Protein Deficiency, Training Group, Sensitivity, Fatigue, Muscular Atrophy
- Trial name
- NCT05769101
- Testing
- Ingestion of a Post-Workout Supplement, Ingestion of a Maltodextrin Supplement
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Joel Puente
HIV Infections, HIV Seronegativity
ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
The purpose of this study is to test how the body's immune system responds to the vaccine ALVAC-HIV vCP1452 and to determine if the vaccine is safe when given alone and with MN rgp120.
- Trial name
- NCT00011037
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1
- Where
- 4 sites in Brazil, Haiti and 2 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.
- Trial name
- NCT03382418
- Testing
- gp145 C.6980 Vaccine, Aluminum Hydroxide Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
To determine the safety and immunogenicity of rgp120/HIV-1SF2 combined with MF59 adjuvant emulsion versus MF59 alone in HIV-negative volunteers.
- Trial name
- NCT00000832
- Testing
- MF59, rgp120/HIV-1 SF-2
- Where
- 4 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens…
- Trial name
- NCT05208125
- Testing
- ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS)., Normal saline solution
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IrsiCaixa
Nutrition Deficiency Due to A Particular Kind of Food
Quality of Protein From the Common Bean
Dietary Protein quality is based on digestion of proteins to amino acids and the bioavailability of the amino acids to maintain good health and body function.
- Trial name
- NCT04118517
- Testing
- Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults
- Where
- Jamaica
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
Hemophilia A
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
The purpose of this study is to evaluate the rate of response when administering rituximab to suppress or eliminate the anti-body in a patient's blood that inhibits the effectiveness of their factor replacement product compared…
- Trial name
- NCT00306670
- Testing
- Rituxan, prednisone
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Overweight, Nutritional Deficiency
The PROTEIN Project
New advances in information computer technology and artificial intelligence (AI) offer the possibility to create a personalized tool and support system for healthy living and eating, and this is the principal objective of the…
- Conditions
- Overweight, Nutritional Deficiency, Poor Nutrition, Iron-deficiency
- Trial name
- PROTEIN (NCT04829851)
- Testing
- PROTEIN Mobile App, Expert Dashboard
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Protein-Energy Malnutrition
FortiPhy: Protein Bioavailability, Satiety and Appetite
Older adults have very specific food and nutrient requirements and often struggle to meet these needs due to poor appetite, reduced functionality and dexterity.
- Trial name
- NCT05512975
- Testing
- Dairy protein porridge arm, Plant protein porridge arm, Control Porridge arm
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Reading
Nutritional Deficiency, Ileostomy; Functional Disturbance
Absorption of Peptides, Fluid, and Electrolytes in Patients With an Ileostomy
Clinical trial, active comparator, cross over, randomised. In total, 12 adults with an ileostomy will be randomised to a sequential 4 weeks intervention with different qualities and sources of protein wish 2-week washout periods.
- Conditions
- Nutritional Deficiency, Ileostomy; Functional Disturbance, Short Bowel Syndrome, Absorption; Disorder, Protein
- Trial name
- ABSOLYT (NCT04141826)
- Testing
- Hydrolysed whey, Intact whey, Caseinate
- Where
- Denmark
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Christian Hvas
HIV Infections
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
To evaluate the safety and immune response to 640 and 1280 mcg HIV-1 recombinant envelope glycoprotein gp160. To evaluate the duration of antibody response and its relationship to dose and frequency of inoculation.
- Trial name
- NCT00000956
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
To determine in healthy HIV-negative volunteers the safety and immunogenicity of rgp120/HIV-1SF2 (BIOCINE) formulated with each of seven adjuvants.
- Trial name
- NCT00001042
- Testing
- Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)